Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.44 |
| ▸ | CDC7 | O00311 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 2/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30177058 | 1.00 | MAOB (0.49) | MAOBMKNK1CDC7P2RX7EIF2AK2 | |
| SCHEMBL22768248 | 0.88 | P2RX7 (0.41) | MAOBMKNK1CDC7P2RX7EIF2AK2 | |
| SCHEMBL21856670 | 0.86 | CDC7 (0.53) | MKNK1CDC7NOS1METAP2CSNK2A1 | |
| SCHEMBL30176980 | 0.86 | CDC7 (0.53) | MKNK1CDC7NOS1METAP2CSNK2A1 | |
| SCHEMBL22768570 | 0.85 | AXL (0.51) | MAOBMKNK1KDRAXL | |
| SCHEMBL21856798 | 0.81 | CDC7 (0.53) | MKNK1CDC7NOS1METAP2CSNK2A1 | |
| SCHEMBL26321249 | 0.81 | NOS1 (0.41) | MKNK1CDC7EIF2AK2NOS1METAP2 | |
| SCHEMBL21856857 | 0.80 | MAPT (0.52) | NOS1DYRK1A | |
| SCHEMBL30936725 | 0.77 | MAOB (0.40) | MAOBMKNK1CDC7TRPA1 | |
| SCHEMBL27216867 | 0.77 | MAOB (0.40) | MAOBMKNK1CDC7TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240336614-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2024-10-10 | — | — | US | disclosed |
| US-11884672-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| CN-115776984-A | Pyrrolo [2,3-f ] indazole and 2,4,5, 10-tetraazatricyclo [7.3.0.03,7] dodec-1, 3 (7), 5,8, 11-pentaene derivatives as alpha-1-antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4126877-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-3969440-A1 | CONDENSED TRICYCLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114096542-A | Condensed tricyclic pyrroles as alpha-1 antitrypsin modulators | 弗特克斯药品有限公司 | 2022-02-25 | — | — | CN | disclosed |
| WO-2021203010-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336614-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | MAOB 1462/4885MKNK1 2524/4885CDC7 3618/4885 |
| US-11884672-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINC1, SERPINA3 | MAOB 1462/4885MKNK1 2524/4885CDC7 3618/4885 |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | MAOB 1462/4885MKNK1 2524/4885CDC7 3618/4885 |
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINC1, SERPINA3 | MAOB 1462/4885MKNK1 2524/4885CDC7 3618/4885 |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINA3, SERPINC1 | MAOB 2710/4885MKNK1 2403/4885CDC7 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.